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Abstract
In a stratified clinical trial design with time to event end points, stratification factors are often accounted
for the log-rank test and the Cox regression analyses. In this work, we have evaluated the impact of
inclusion of stratification factors on the power of the stratified log-rank test and have compared the bias
and standard error in HR estimate between multivariate and stratified Cox regression analyses through
simulation. Results from our investigation suggests that both failing to consider stratification factor in
presence of their prognostic effect and stratification with smaller number of events may substantially
reduce the power of the log-rank test. Further, the HR estimate from the multivariate Cox analysis
is more accurate and precise compared to the stratified Cox analysis. Our findings point towards the
necessity of evaluating the impact of stratification factors on the time to event analyses at the time of
study design which is presently not a norm.
Keywords: Multivariate Cox analysis, Stratified Cox analysis, Stratified Log-rank test, Stratifica-
tion factors.
In clinical trials comparing time to event endpoints such as progression free survival (PFS) or overall
survival (OS) between two treatment arms, some baseline covariates can influence the treatment ben-
efit either due to their prognostic effect or their association with treatment responsiveness [1, 2, 3].
To address this, often stratified randomization is employed considering these baseline covariates as
stratification factors. The regulatory guidelines [3, 4] suggest to include the stratification factors
on which randomization has been stratified later in the analysis stage and accounting for them in
the analysis stage are seen as complementary to stratified randomization. In compliance with these
guidelines, hypothesis testing are generally carried out in clinical trials using stratified log-rank test
whereas treatment effects are quantified using hazards ratio (HR) from stratified or multivariate Cox
regression model. Given the strengths and weaknesses of both stratified and multivariate analyses
and the mixed practice, the purpose of this work is to evaluate the impact of inclusion of stratification
factors on the power of stratified log-rank test and to compare the bias and standard error in HR
estimate between multivariate and stratified Cox regression analyses through simulations.
To put it simply, under stratified log-rank test, test statistics are derived separately within each
stratum and then added together instead of deriving test statistic based on the entire population as
done in standard unstratified log-rank test. Similarly, in the stratified Cox regression model, HR is
calculated within each stratum and then combine these HR to obtain a global HR [5]. An alternative
approach to the stratified Cox regression model is to use multivariate Cox regression model where
stratification factors are passed as covariates in addition to the treatment, as originally proposed by
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Cox [6]. In our observation, majority of recently published pivotal clinical trials (e.g., see [7, 8, 9, 10])
have reported HR based on stratified Cox regression analysis whereas the use of multivariate Cox
model has been very limited in recent times [11, 12]. In some cases, HR from both the models are
reported [13]. The use of multivariate Cox model is limited to exploratory analysis [14] or the clinical
trials with small sample size [15, 16].
Rational for using stratified log-rank test and stratified Cox regression analysis stems from the need
to control the prognostic effects of stratification variables, a common rational to any other stratified
analysis as well. However, stratification may cause loss of power [17, 18]and estimate of HR may
not be stable [2], especially when the number of strata is very large relative to the sample size. On
contrary, although multivariate Cox model leads to more stable estimate, it’s use has been criticized
as it may lead to biased estimate of HR due to the strong assumption that stratification factors have a
multiplicative effect on the hazard rate [19]. Akazawa et. al. [17] carried out simulations to compare
power between stratified log-rank test and the standard log-rank test primarily under two scenarios:
first, there is no prognosis effect of stratification factors and second, the stratification factors affect the
true HR. Ding and Sinha [20] compared power between these stratified and multivariate Cox models,
but they did not report the bias or standard error in HR estimation. We have carried out simulation
to evaluate the properties (i.e., power, bias and standard error) of stratified and multivariate analyses
under a more realistic clinical trial scenario with prognostic effect of stratification factors limited to
the baseline hazards within each strata but not on the treatment effect measured by treatment to
control HR. Precisely, we have considered a randomized two arms clinical trial comparing treatment
arm with control arm with 14 months of accrual, 12 strata based on 3 stratification factors: X1
(with 2 levels), X2 (with 3 levels) and X3 (with 2 levels). Our simulation was carried out to reflect
following three distinct scenarios:
• Scenario 1 (No prognostic effect): No effects of stratification factors.
• Scenario 2 (Multivariate Cox model): Prognostic effect of stratification factors on baseline
hazards (but not the treatment to control HR) in consistent with multivariate Cox model.
• Scenario 3 (Stratified Cox model): Prognostic effect of stratification factors on baseline hazards
(but not the treatment to control HR) that is not consistent with multivariate Cox model.
Event times for the control arm were generated as follows: (a) under “no prognostic effect” model,
from a hazards function with median time as 16 months, (b) under “multivariate Cox model”, from
hazard function λ(t|x) = λ(t) exp(βx1x1 + βx21x21 + βx22x22 + βx3x3) for stratum X1 = x1,X2 =
(x21, x22),X3 = x3 with X21 and X22 being the indicator variables for X2, λ(t) = log(2)/16,
exp(βx1) = 0.5, exp(βx21) = 0.75, exp(βx22) = 1.25 and exp(βx3) = 0.75 translating strata spe-
cific median time as 16, 21.3, 21.3, 28.4, 12.8, 17.1, 32, 42.7, 42.7, 56.9, 25.6 and 34.1 months,
respectively, and (c) under “stratified Cox model”, from stratum specific 12 distinct baseline hazard
functions (not consistent with multiplicative nature of a multivariate Cox model) with corresponding
median as 16, 16, 16, 16, 16, 16, 50, 50, 50, 50, 50 and 50 months. Within each stratum, event times
under both the treatment arm and the control arm were generated according to exponential distri-
bution with hazard rate for the treatment arm obtained by multiplying control hazard rate with the
true HR (0.50 to 0.75). Further, for each patients, enrollment times were generated randomly from
uniform distribution and assignments to the treatment arms were made according to the Bernoulli
distribution with equal probabilities reflecting 1:1 randomization. Multivariate Cox model was fitted
including treatment indicator variable and X1, X2 and X3 as covariates without any interaction
term as suggested in [4]. Stratified Cox model was fitted including X1, X2 and X3 as stratification
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factors and treatment as the only covariate. Simulations were carried out with minimum events
(D) sufficient for 80% power with corresponding sample sizes as D/0.70. Strata sizes were varied
from balanced strata size to unabalanced strata sizes towards strata with better prognosis or poor
prognosis. Simulation codes are included as supplementary material to this paper.
Table 1 summarize the results based on 10,000 simulations under all three scenarios for multivariate
Cox analysis and stratified analysis. Results from unstratified analyses which includes simple Cox
regression and standard log-rank test without considering any stratification factors are also provided.
In presence of prognostic effects of stratification factors (see Scenario 2 and 3), the power from un-
stratified analyses are consistently smaller than the power of stratified and multivariate analyses,
largely driven by larger bias towards null in unstratified analyses. The power of unstratified log-rank
test remains substantially smaller than the nominal 80% power even in studies with larger number
of events. This finding together with the power loss with unstratified log-rank test in presence of
prognostic effects on HR reported by Akazawa et al. [17] underlines the need to account for strati-
fication factors in time to events analyses. The performance of unstratified analyses improves with
unbalance in strata size as this increases degree of homogeneity in overall sample compared to the
sample with balanced strata size in which case degree of heterogeneity is at its maximum.
Under all the three scenarios (Scenario 1 - 3), the power of stratified log-rank test is consistently
smaller than nominal power when number of events is small, but it gradually catches up to nominal
80% power with the increase in the number of required events. This is consistent with the mathemat-
ical argument that the power of log-rank test is adversely affected by extreme value for the ratio of
the number of patients at risk in the two treatment groups and such extreme values are more frequent
in case of stratification [17]. In comparison with standard Cox regression analysis, the HR estimate
from stratified Cox regression analysis has greater standard error in consistent with analytical proof
provided by Feng et al. [18]. In relative assessment between stratified and multivariate analyses, the
HR estimate from multivariate Cox model is less biased and more precise (i.e., less standard error)
than that of stratified Cox model under all scenario including when the data is generated under
“stratified Cox model”. Due to greater bias and higher standard error, stratified Cox analysis has
less power compared to multivariate Cox analysis, as observed previously [20], implying that 95%
confidence interval for HR estimated from stratified Cox analysis is more likely to include 1. The
difference in performance between stratified and multivariate analyses gradually fades away when
study is designed with higher number of events. Our findings suggest that for studies with smaller
number events, multivariate analysis would be prudent choice; however, as the number of events
increases to 380, both the stratified and multivariate seem to be equally efficient.
Results from our investigation suggests that both failing to consider stratification factor in presence
of their prognostic effect and stratification with smaller number of events may substantially reduce
the power of log-rank test and at times this power loss exceeds 10%. Noting that stratified log-
rank test is often more obvious choice and recommended in regulatory guidelines, one must be very
considerate about the power loss due to stratification when designing studies with smaller number
of events. Presently, studies with stratified log-rank test are regularly designed based on unstratified
log-rank without any care given to loss of power due to stratification. A much desired strategy would
be to assess the loss of power due to stratification in the design stage and should compensate for
that by increasing the target number of events to avoid designing an under-powered study. Our
simulation results indicate that HR estimates from multivariate Cox analysis are relatively more
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Table 1: Performance of Cox models (multivariate and stratified) and log-rank tests (stratified and
unstratified) in estimating and testing HR (treatment to control) based on 10,000 simulations
Average Bias Average SE Average MSE
in HR estimate in HR estimate in HR estimate Power(%)
True Eve- Mult Strat Mult Strat Mult Strat Strat Mult Strat
Strata size (ratio) HR nts Cox Cox Cox Cox Cox Cox Cox Cox Cox LR LR Cox Cox
Simulation scenario 1: no prognostic effect of stratification factors
Balanced strata size 0.5 66 0.015 0.007 0.016 0.255 0.262 0.294 0.018 0.019 0.024 79.1 68.6 78.1 67.8
Ratio of size: 0.55 88 0.014 0.009 0.015 0.219 0.223 0.244 0.016 0.016 0.02 78.7 70.6 78.2 70.2
1:1:1:1:1:1:1:1:1:1:1:1 0.6 120 0.009 0.006 0.01 0.186 0.188 0.2 0.013 0.014 0.015 79 73.9 78.4 73.5
0.65 170 0.01 0.008 0.01 0.156 0.157 0.164 0.011 0.011 0.012 78.8 74.6 78.3 74.5
0.7 248 0.006 0.004 0.006 0.128 0.129 0.133 0.008 0.008 0.009 79.8 77.2 79.6 77.1
0.75 380 0.004 0.003 0.004 0.103 0.104 0.106 0.006 0.006 0.006 79.4 77.5 79 77.4
Simulation scenario 2: Multivariate Cox model
Balanced strata size 0.5 66 0.049 0.016 0.019 0.254 0.262 0.297 0.022 0.02 0.024 71.2 67.1 75.9 66.6
Ratio of size: 0.55 88 0.044 0.012 0.013 0.218 0.224 0.247 0.019 0.017 0.02 71.3 69.7 76.6 69.2
1:1:1:1:1:1:1:1:1:1:1:1 0.6 120 0.036 0.012 0.011 0.186 0.189 0.201 0.016 0.014 0.016 72.8 73.3 77.1 73
0.65 170 0.031 0.01 0.008 0.155 0.157 0.164 0.012 0.011 0.012 73.1 75.6 77.7 75.3
0.7 248 0.028 0.009 0.006 0.128 0.129 0.133 0.01 0.009 0.009 73.1 76.8 78.3 76.6
0.75 380 0.022 0.007 0.004 0.103 0.104 0.106 0.007 0.006 0.006 72.7 78 78.1 77.9
Unbalanced (more 0.5 66 0.035 0.015 0.018 0.255 0.262 0.292 0.02 0.02 0.024 75.3 68.7 76.7 68
subjects in strata 0.55 88 0.031 0.014 0.014 0.219 0.224 0.245 0.018 0.017 0.02 74.8 70 76.8 69.6
with better prognosis) 0.6 120 0.024 0.011 0.009 0.186 0.189 0.201 0.014 0.014 0.015 76 74.3 78.2 74
Ratio of size: 0.65 170 0.023 0.012 0.009 0.155 0.157 0.165 0.012 0.011 0.012 75.2 74.7 77.4 74.4
1:1:1:1:1:1:7:7:7:7:7:7 0.7 248 0.018 0.008 0.005 0.128 0.129 0.134 0.009 0.008 0.009 76.4 76.9 78.7 76.7
0.75 380 0.015 0.007 0.003 0.103 0.104 0.106 0.006 0.006 0.006 75.8 77.7 78.7 77.5
Unbalanced (more 0.5 66 0.035 0.013 0.018 0.255 0.262 0.284 0.02 0.02 0.023 74.7 70.6 77.2 70
subjects in strata 0.55 88 0.032 0.013 0.013 0.218 0.223 0.238 0.018 0.017 0.019 74.3 72.1 77 71.6
with poor prognosis) 0.6 120 0.021 0.009 0.009 0.186 0.188 0.196 0.014 0.014 0.014 76.2 75.3 78 75.1
Ratio of size: 0.65 170 0.019 0.007 0.007 0.155 0.157 0.162 0.011 0.011 0.012 76.1 77.2 78.9 76.9
7:7:7:7:7:7:1:1:1:1:1:1 0.7 248 0.017 0.007 0.005 0.128 0.129 0.132 0.009 0.009 0.009 75.7 77.2 78.4 77
0.75 380 0.013 0.004 0.002 0.103 0.104 0.105 0.006 0.006 0.006 76.3 79.1 78.5 79
Simulation scenario 3: Stratified Cox model
Balanced strata size 0.5 66 0.071 0.006 0.017 0.253 0.264 0.299 0.026 0.02 0.025 65.7 66.6 77.8 65.9
Ratio of size: 0.55 88 0.066 0.005 0.012 0.218 0.225 0.249 0.023 0.017 0.02 65.4 69.7 78.2 69.1
1:1:1:1:1:1:1:1:1:1:1:1 0.6 120 0.056 0.004 0.009 0.185 0.189 0.202 0.018 0.014 0.015 66.4 73.3 79.4 72.9
0.65 170 0.049 0.003 0.006 0.155 0.157 0.165 0.014 0.011 0.012 67 75.5 79.8 75.3
0.7 248 0.045 0.004 0.007 0.128 0.129 0.134 0.011 0.009 0.009 65.9 76.1 79 75.9
0.75 380 0.038 0.003 0.004 0.103 0.104 0.106 0.008 0.006 0.006 65.5 77.7 79.8 77.6
Unbalanced (more 0.5 66 0.037 0.006 0.016 0.255 0.264 0.294 0.021 0.02 0.024 74.4 68.6 78 67.9
subjects in strata 0.55 88 0.038 0.008 0.016 0.219 0.225 0.247 0.018 0.016 0.02 73 69.4 77.7 69
with better prognosis) 0.6 120 0.03 0.004 0.009 0.186 0.189 0.202 0.015 0.014 0.016 73.5 73.3 78.7 72.9
Ratio of size: 0.65 170 0.026 0.006 0.008 0.155 0.157 0.166 0.012 0.011 0.012 74.3 74.7 78.8 74.4
1:1:1:1:1:1:7:7:7:7:7:7 0.7 248 0.023 0.004 0.006 0.128 0.129 0.134 0.009 0.008 0.009 74.5 76.4 79.9 76.2
0.75 380 0.016 0.002 0.003 0.103 0.104 0.107 0.007 0.006 0.006 75.2 77.9 80.2 77.7
Unbalanced (more 0.5 66 0.032 0.004 0.013 0.255 0.261 0.282 0.02 0.019 0.022 75.7 72.7 79 72.1
subjects in strata 0.55 88 0.034 0.008 0.014 0.218 0.223 0.237 0.018 0.016 0.019 73.6 73 78.3 72.5
with poor prognosis) 0.6 120 0.023 0.007 0.011 0.186 0.188 0.195 0.014 0.014 0.015 75.8 75.7 78.3 75.5
Ratio of size: 0.65 170 0.019 0.004 0.006 0.155 0.157 0.161 0.011 0.011 0.012 76.6 77.5 79.8 77.4
7:7:7:7:7:7:1:1:1:1:1:1 0.7 248 0.018 0.004 0.005 0.128 0.129 0.131 0.009 0.008 0.009 75.3 78.3 79.6 78.2
0.75 380 0.014 0.002 0.004 0.103 0.104 0.105 0.006 0.006 0.006 76.5 79.3 80.4 79.2
-Mult: Multivariate; Strat: Stratified; Unstrat: Unstratified; LR: Log-rank test; SE: Standard error; HR: treatment
arm to control arm hazards ratio
-Events (D) were set at required events for 80% power with 2.5% type-I error rate.
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accurate and precise compared to stratified Cox analysis even when the data was not generated
from multivariate Cox model. This finding goes quite well with the present understanding that
stratification compromises with the stability of estimate of HR. The possible explanation for the
smaller bias with multivariate Cox analysis even under “stratified Cox model” is that multivariate
Cox model can adapt to the data better so that it can produce a estimate closer the truth. Our
simulation is not exhaustive (e.g., it did not consider the prognostic effect on treatment to control
HR) and findings are not absolute, however, it raises serious point about the necessity of evaluating
the impact of stratification factors in time to event analyses.
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